Academic Journal

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial

التفاصيل البيبلوغرافية
العنوان: Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial
المؤلفون: Opdam, Mark, van Rossum, Annelot G.J., Hoogstraat, Marlous, Bounova, Gergana, Horlings, Hugo M., van Werkhoven, Erik, Mandjes, Ingrid A.M., van Leeuwen – Stok, A. Elise, Canisius, Sander, van Tinteren, Harm, Imholz, Alex L.T., Portielje, Johanneke E.A., Bos, Monique E.M.M., Bakker, Sandra, Wesseling, Jelle, Kester, Lennart, van Rheenen, Jacco, Rutgers, Emiel J., de Menezes, Renee X., Wessels, Lodewyk F.A., Kok, Marleen, Oosterkamp, Hendrika M., Linn, Sabine C., the MATADOR trialists’ group for the Dutch Breast Cancer Research Group (BOOG)
المساهمون: Pathologie, Cancer, Urologie Opleiding, MS Medische Oncologie
سنة النشر: 2024
مصطلحات موضوعية: Cancer, Clinical genetics, Oncology, General
الوصف: The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene expression profile that can predict benefit from either docetaxel, doxorubicin, and cyclophosphamide (TAC) or dose-dense scheduled doxorubicin and cyclophosphamide (ddAC). Patients with a pT1-3, pN0-3 tumor were randomized 1:1 between ddAC and TAC. The primary endpoint was a gene profile-treatment interaction for recurrence-free survival (RFS). We observed 117 RFS events in 664 patients with a median follow-up of 7 years. Hallmark gene set analyses showed significant association between enrichment in immune-related gene expression and favorable outcome after TAC in hormone receptor-negative, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) (triple-negative breast cancer [TNBC]). We validated this association in TNBC patients treated with TAC on H&E slides; stromal tumor-infiltrating lymphocytes (sTILs) ≥20% was associated with longer RFS (hazard ratio 0.18, p = 0.01), while in patients treated with ddAC no difference in RFS was seen (hazard ratio 0.92, p = 0.86, pinteraction = 0.02).
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
تدمد: 2589-0042
Relation: https://dspace.library.uu.nl/handle/1874/455339
الاتاحة: https://dspace.library.uu.nl/handle/1874/455339
Rights: info:eu-repo/semantics/OpenAccess
رقم الانضمام: edsbas.96C0461E
قاعدة البيانات: BASE